Adcock Ingram Pharma Profile
Key Indicators
- Authorised Capital ₹ 60.50 Cr
as on 29-10-2024
- Paid Up Capital ₹ 60.50 Cr
as on 29-10-2024
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 50.50 Cr
as on 29-10-2024
- Revenue -88.45%
(FY 2023)
- Profit -344.67%
(FY 2023)
- Ebitda -10.01%
(FY 2023)
- Net Worth 107.11%
(FY 2023)
- Total Assets 108.86%
(FY 2023)
About Adcock Ingram Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 60.50 Cr and a paid-up capital of Rs 60.50 Cr.
The company currently has active open charges totaling ₹50.50 Cr.
The Key Managerial Personnel (KMP) at Adcock Ingram Pharma Private Limited India are Alok Sharma as COMPANY SECRETARY and Chandra Mohan as Cfo. Ammanna Yarlagadda, Shanthakumarie Pather, Yudhveer Singh, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24299KA2021PTC148184
- Company No.
148184
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 2021
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Adcock Ingram Pharma?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Alok Sharma | Company Secretary | 21-Jun-2022 | Current |
Ammanna Yarlagadda  | Managing Director | 21-Sep-2022 | Current |
| Chandra Mohan | CFO | 02-Aug-2023 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yasuhiro Nakagiri  | Additional Director | 20-Jun-2024 | Current |
| Pravin Iyer | Director | 07-Jun-2021 | Current |
| Pankaj Garg | Director | 07-Jun-2021 | Current |
Shanthakumarie Pather  | Director | 28-Sep-2022 | Current |
| Yudhveer Singh | Director | 24-Jan-2022 | Current |
| Kenshi Murase | Director | 11-Jun-2021 | Current |
Financial Performance and Corporate Structure Insights of Adcock Ingram Pharma.
Adcock Ingram Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 88.45% decrease. The company also saw a substantial fall in profitability, with a 344.67% decrease in profit. The company's net worth Soared by an impressive increase of 107.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adcock Ingram Pharma?
In 2023, Adcock Ingram Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Adcock Ingram LimitedActive 17 years 8 monthsAlok Sharma, Ammanna Yarlagadda and 6 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Mar 2022 | ₹50.50 Cr | Open |
How Many Employees Work at Adcock Ingram Pharma?
Adcock Ingram Pharma has a workforce of 67 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adcock Ingram Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adcock Ingram Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
